

BBS-Bioactive Bone Substitutes Plc: The website's functionality restored

BBS-Bioactive Bone Substitutes Plc | Press Release | April 05, 2024 at 13:30:00 EEST

The company announced on 26 March 2024 that its website had been attacked. The attacker managed to install disruptive malware on the website. The malicious code has now been removed, and the website's functionality restored.

No information important to the company has been leaked.

For more information, please contact:

Juliusz Rakowski, CEO +358 50 448 5132 juliusz.rakowski@bbs-artebone.fi

Certified Advisor:

Nordic Certified Adviser AB, +46 70 551 67 29, info@certifiedadviser.se

Distribution

Nasdaq Helsinki https://www.bbs-artebone.fi/

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: <u>www.bbs-artebone.fi</u>